Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Laboratories, |
RCV001508717 | SCV001715055 | likely pathogenic | not provided | 2020-12-09 | criteria provided, single submitter | clinical testing | PS3, PS4_moderate, PM1, PM2, PP1 |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003479334 | SCV004223564 | pathogenic | Congenital factor VII deficiency | 2023-11-09 | criteria provided, single submitter | clinical testing | Variant summary: F7 c.920G>A (p.Arg307His) results in a non-conservative amino acid change located in the Serine proteases, trypsin domain (IPR001254) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 248952 control chromosomes. c.920G>A, also known as p.Arg247His has been reported at a homozygous state in at-least four individuals affected with Congenital factor VII deficiency (examples, Trujillano_2017, Ohiwa_1994). Furthermore, this variant at a heterozygous state, was reported in one individual with bleeding symptoms including gum bleed, hematomas and reduced FVII levels (Herrmann_2009) and in several relatives with moderately impaired prothrombin time, reduced levels and activities of factor VII antigen (Ohiwa_1994). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in impaired secretion of the mutated factor VII (about 58% of WT) (Ohiwa_1994). The following publications have been ascertained in the context of this evaluation (PMID: 7974346, 27848944, 18976247). One submitter has cited clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
| Center for Genomic Medicine, |
RCV003479334 | SCV004804791 | likely pathogenic | Congenital factor VII deficiency | 2024-03-17 | criteria provided, single submitter | research | |
| OMIM | RCV001843373 | SCV000033091 | pathogenic | Factor VII deficiency | 1994-06-01 | no assertion criteria provided | literature only | |
| Prevention |
RCV004753349 | SCV005345841 | likely pathogenic | F7-related disorder | 2024-06-26 | no assertion criteria provided | clinical testing | The F7 c.920G>A variant is predicted to result in the amino acid substitution p.Arg307His. This variant was reported in the homozygous state in individuals with clinically asymptomatic Factor VII deficiency; in vitro functional studies indicated that this variant results in impaired secretion (Ohiwa et al. 1994. PubMed ID: 7974346). This variant was also described in the homozygous state in an individual with an abnormality of coagulation (Trujillano et al. 2016. PubMed ID: 27848944, supplementary data). This variant is reported in 0.0081% of alleles in individuals of African descent in gnomAD. Taken together, we classify this variant as likely pathogenic. |